Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2024

07-12-2023 | Bronchial Asthma | REVIEW

Osteopontin: A Novel Therapeutic Target for Respiratory Diseases

Authors: Qi Jia, Yeling Ouyang, Yiyi Yang, Shanglong Yao, Xiangdong Chen, Zhiqiang Hu

Published in: Lung | Issue 1/2024

Login to get access

Abstract

Osteopontin (OPN) is a multifunctional phosphorylated protein that is involved in physiological and pathological events. Emerging evidence suggests that OPN also plays a critical role in the pathogenesis of respiratory diseases. OPN can be produced and secreted by various cell types in lungs and overexpression of OPN has been found in acute lung injury/acute respiratory distress syndrome (ALI/ARDS), pulmonary hypertension (PH), pulmonary fibrosis diseases, lung cancer, lung infection, chronic obstructive pulmonary disease (COPD), and asthma. OPN exerts diverse effects on the inflammatory response, immune cell activation, fibrosis and tissue remodeling, and tumorigenesis of these respiratory diseases, and genetic and pharmacological moudulation of OPN exerts therapeutic effects in the treatment of respiratory diseases. In this review, we summarize the recent evidence of multifaceted roles and underlying mechanisms of OPN in these respiratory diseases, and targeting OPN appears to be a potential therapeutic intervention for these diseases.
Literature
1.
Sécher T, Guilleminault L, Reckamp K et al (2018) Therapeutic antibodies: a new era in the treatment of respiratory diseases? Pharmacol Ther 189:149–172PubMedCrossRef
2.
Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287(5454):860–864PubMedCrossRefADS
3.
Chen G, Zhang X, Li R et al (2010) Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum 62(10):2900–2908PubMedCrossRef
4.
Sawaki D, Czibik G, Pini M et al (2018) Visceral adipose tissue drives cardiac aging through modulation of fibroblast senescence by osteopontin production. Circulation 138(8):809–822PubMedCrossRef
5.
Szalay G, Sauter M, Haberland M et al (2009) Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Cir Res 104(7):851–859CrossRef
6.
Khamissi FZ, Ning L, Kefaloyianni E et al (2022) Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure. Sci Adv 8(8):eabm5900PubMedPubMedCentralCrossRef
7.
8.
Fu Y, Zhang Y, Lei Z et al (2020) Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol 13(1):169PubMedPubMedCentralCrossRef
9.
Morimoto Y, Hirahara K, Kiuchi M et al (2018) Amphiregulin-producing pathogenic memory T helper 2 cells instruct Eosinophils to secrete osteopontin and facilitate airway fibrosis. Immunity 49(1):134-150.e136PubMedCrossRef
10.
Saker M, Lipskaia L, Marcos E et al (2016) Osteopontin, a key mediator expressed by senescent pulmonary vascular cells in pulmonary hypertension. Arterioscler Thromb Vasc Biol 36(9):1879–1890PubMedCrossRef
11.
12.
13.
Shi L, Sun Z, Su W et al (2021) Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke. Immunity 54(7):1527-1542.e1528PubMedPubMedCentralCrossRef
14.
Fong YC, Liu SC, Huang CY et al (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64(3):263–270PubMedCrossRef
15.
Dai J, Peng L, Fan K et al (2009) Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28(38):3412–3422PubMedCrossRef
16.
Leavenworth JW, Verbinnen B, Wang Q et al (2015) Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci USA 112(2):494–499PubMedCrossRefADS
17.
Shinohara ML, Kim JH, Garcia VA et al (2008) Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 29(1):68–78PubMedPubMedCentralCrossRef
18.
19.
Rizzello C, Cancila V, Sangaletti S et al (2022) Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling. Mol Cancer 21(1):215PubMedPubMedCentralCrossRef
20.
Christensen B, Petersen TE, Sørensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411(1):53–61PubMedCrossRef
21.
Kaartinen MT, Pirhonen A, Linnala-Kankkunen A et al (1999) Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J Biol Chem 274(3):1729–1735PubMedCrossRef
22.
Yokosaki Y, Tanaka K, Higashikawa F et al (2005) Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 24(6):418–427PubMedCrossRef
23.
Bayless KJ, Davis GE (2001) Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol Chem 276(16):13483–13489PubMedCrossRef
24.
Weber GF, Ashkar S, Glimcher MJ et al (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271(5248):509–512PubMedCrossRefADS
25.
Sun BS, Li Y, Zhang ZF et al (2013) Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96(6):1943–1951PubMedCrossRef
26.
Kim JS, Bashir MM, Werth VP (2012) Gottron’s papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 132(7):1825–1832PubMedPubMedCentralCrossRef
27.
28.
Mukherjee BB, Nemir M, Beninati S et al (1995) Interaction of osteopontin with fibronectin and other extracellular matrix molecules. Ann N Y Acad Sci 760:201–212PubMedCrossRefADS
29.
Christensen B, Nielsen MS, Haselmann KF et al (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390(Pt 1):285–292PubMedPubMedCentralCrossRef
30.
31.
Jono S, Peinado C, Giachelli CM (2000) Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275(26):20197–20203PubMedCrossRef
32.
Minai-Tehrani A, Chang SH, Park SB et al (2013) The O-glycosylation mutant osteopontin alters lung cancer cell growth and migration in vitro and in vivo. Int J Mol Med 32(5):1137–1149PubMedCrossRef
33.
Christensen B, Zachariae ED, Scavenius C et al (2016) Transglutaminase 2-catalyzed intramolecular cross-linking of osteopontin. Biochemistry 55(2):294–303PubMedCrossRef
34.
Higashikawa F, Eboshida A, Yokosaki Y (2007) Enhanced biological activity of polymeric osteopontin. FEBS Lett 581(14):2697–2701PubMedCrossRef
35.
Forsprecher J, Wang Z, Goldberg HA et al (2011) Transglutaminase-mediated oligomerization promotes osteoblast adhesive properties of osteopontin and bone sialoprotein. Cell Adh Migr 5(1):65–72PubMedPubMedCentralCrossRef
36.
Bos LDJ, Ware LB (2022) Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet 400(20358):1145–1156PubMedCrossRef
37.
Wang J, Li X, Wang Y et al (2022) Osteopontin aggravates acute lung injury in influenza virus infection by promoting macrophages necroptosis. Cell Death Discov 8(1):97PubMedPubMedCentralCrossRef
38.
Hayek SS, Roderburg C, Blakely P et al (2021) Circulating osteopontin levels and outcomes in patients hospitalized for COVID-19. J Clin Med 10(17):3907PubMedPubMedCentralCrossRef
39.
Tonello S, D’Onghia D, Apostolo D et al (2023) Baseline plasma osteopontin protein elevation predicts adverse outcomes in hospitalized COVID-19 patients. Viruses 15(3):630PubMedPubMedCentralCrossRef
40.
Kasetty G, Papareddy P, Bhongir RKV et al (2019) Osteopontin protects against lung injury caused by extracellular histones. Mucosal Immunol 12(1):39–50PubMedCrossRef
41.
42.
Zhu Y, Wei Y, Chen J et al (2015) Osteopontin exacerbates pulmonary damage in influenza-induced lung injury. Jpn J Infect Dis 68(6):467–473PubMedCrossRef
43.
Zhao H, Chen Q, Huang H et al (2019) Osteopontin mediates necroptosis in lung injury after transplantation of ischaemic renal allografts in rats. Br J Anaesth 123(4):519–530PubMedCrossRef
44.
Kapur R, Kasetty G, Rebetz J et al (2019) Osteopontin mediates murine transfusion-related acute lung injury via stimulation of pulmonary neutrophil accumulation. Blood 134(1):74–84PubMedCrossRef
45.
Takahashi F, Takahashi K, Shimizu K et al (2004) Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung 182(3):173–185PubMedCrossRef
46.
47.
Chen L, Yang J, Zhang M et al (2023) SPP1 exacerbates ARDS via elevating Th17/Treg and M1/M2 ratios through suppression of ubiquitination-dependent HIF-1α degradation. Cytokine 164:156107PubMedCrossRef
48.
Humbert M, Guignabert C, Bonnet S et al (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53(1):1801887PubMedPubMedCentralCrossRef
49.
Lorenzen JM, Nickel N, Krämer R et al (2011) Osteopontin in patients with idiopathic pulmonary hypertension. Chest 139(5):1010–1017PubMedCrossRef
50.
Bellan M, Piccinino C, Tonello S et al (2021) Role of osteopontin as a potential biomarker of pulmonary arterial hypertension in patients with systemic sclerosis and other connective tissue diseases (CTDs). Pharmaceuticals (Basel) 14(5):394PubMedCrossRef
51.
Kölmel S, Hobohm L, Käberich A et al (2019) Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension. Thromb Haemost 119(8):1332–1346PubMedCrossRef
52.
Meng L, Liu X, Teng X et al (2019) Osteopontin plays important roles in pulmonary arterial hypertension induced by systemic-to-pulmonary shunt. FASEB J 33(6):7236–7251PubMedCrossRef
53.
Mura M, Cecchini MJ, Joseph M et al (2019) Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. Respirology 24(11):1104–1110PubMedCrossRef
54.
Anwar A, Li M, Frid MG et al (2012) Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 303(1):L1–L11PubMedPubMedCentralCrossRef
55.
Peng LY, Yu M, Yang MX et al (2020) Icotinib attenuates monocrotaline-induced pulmonary hypertension by preventing pulmonary arterial smooth muscle cell dysfunction. Am J Hypertens 33(8):775–783PubMedCrossRef
56.
Matsui Y, Rittling SR, Okamoto H et al (2003) Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23(6):1029–1034PubMedCrossRef
57.
Zhao H, Wang Y, Qiu T et al (2020) Autophagy, an important therapeutic target for pulmonary fibrosis diseases. Clin Chim Acta 502:139–147PubMedCrossRef
58.
59.
Wolak T, Kim H, Ren Y et al (2009) Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76(1):32–43PubMedCrossRef
60.
Huang R, Hao C, Wang D et al (2021) SPP1 derived from silica-exposed macrophage exosomes triggers fibroblast transdifferentiation. Toxicol Appl Pharmacol 422:115559PubMedCrossRef
61.
Phan THG, Paliogiannis P, Nasrallah GK et al (2021) Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci 78(5):2031–2057PubMedCrossRef
62.
Kumar A, Elko E, Bruno SR et al (2022) Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis. Thorax 77(7):669–678PubMedCrossRef
63.
Takahashi F, Takahashi K, Okazaki T et al (2001) Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 24(3):264–271PubMedCrossRef
64.
Hatipoglu OF, Uctepe E, Opoku G et al (2021) Osteopontin silencing attenuates bleomycin-induced murine pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biomed Pharmacother 139:111633PubMedCrossRef
65.
Pardo A, Gibson K, Cisneros J et al (2005) Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PloS Med 2(9):e251PubMedPubMedCentralCrossRef
66.
Hou J, Ji J, Chen X et al (2021) Alveolar epithelial cell-derived Sonic hedgehog promotes pulmonary fibrosis through OPN-dependent alternative macrophage activation. FEBS J 288(11):3530–3546PubMedCrossRef
67.
Tardelli M, Zeyda K, Moreno-Viedma V et al (2016) Osteopontin is a key player for local adipose tissue macrophage proliferation in obesity. Mol Metab 5(11):1131–1137PubMedPubMedCentralCrossRef
68.
Nau GJ, Guilfoile P, Chupp GL et al (1997) A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci USA 94(12):6414–6419PubMedPubMedCentralCrossRefADS
69.
Latoche JD, Ufelle AC, Fazzi F et al (2016) Secreted phosphoprotein 1 and sex-specific differences in silica-induced pulmonary fibrosis in mice. Environ Health Perspect 124(8):1199–1207PubMedPubMedCentralCrossRef
70.
Dong J, Ma Q (2017) Osteopontin enhances multi-walled carbon nanotube-triggered lung fibrosis by promoting TGF-β1 activation and myofibroblast differentiation. Part Fiber Toxicol 14(1):18CrossRef
71.
Khaliullin TO, Kisin ER, Murray AR et al (2017) Mediation of the single-walled carbon nanotubes induced pulmonary fibrogenic response by osteopontin and TGF-β1. Exp Lung Res 43(8):311–326PubMedPubMedCentralCrossRef
72.
Hirsch FR, Scagliotti GV, Mulshine JL et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311PubMedCrossRef
73.
Raja R, Kale S, Thorat D et al (2014) Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene 33(16):2053–2064PubMedCrossRef
74.
Qian J, LeSavage BL, Hubka KM et al (2021) Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest 131(16):e146186PubMedPubMedCentralCrossRef
75.
Hu Z, Lin D, Yuan J et al (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11(13):4646–4652PubMedCrossRef
76.
Gu T, Ohashi R, Cui R et al (2009) Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66(2):176–183PubMedCrossRef
77.
Jiang YJ, Chao CC, Chang AC et al (2022) Cigarette smoke-promoted increases in osteopontin expression attract mesenchymal stem cell recruitment and facilitate lung cancer metastasis. J Adv Res 41:77–87PubMedCrossRefADS
78.
Boldrini L, Donati V, Dell’Omodarme M et al (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93(4):453–457PubMedPubMedCentralCrossRef
79.
Shijubo N, Uede T, Kon S et al (1999) Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160(4):1269–1273PubMedCrossRef
80.
Mack PC, Redman MW, Chansky K et al (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26(29):4771–4776PubMedPubMedCentralCrossRef
81.
Isa S, Kawaguchi T, Teramukai S et al (2009) Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4(9):1104–1110PubMedCrossRef
82.
Blasberg JD, Pass HI, Goparaju CM et al (2010) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28(6):936–941PubMedPubMedCentralCrossRef
83.
Sun SJ, Wu CC, Sheu GT et al (2016) Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth. Oncotarget 7(34):55572–55584PubMedPubMedCentralCrossRef
84.
Goparaju CM, Pass HI, Blasberg JD et al (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5(10):1516–1523PubMedPubMedCentralCrossRef
85.
Cui R, Takahashi F, Ohashi R et al (2007) Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57(3):302–310PubMedCrossRef
86.
Senger DR, Ledbetter SR, Claffey KP et al (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149(1):293–305PubMedPubMedCentral
87.
Blasberg JD, Goparaju CM, Pass HI et al (2010) Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 139(6):1587–1593PubMedCrossRef
88.
Shi L, Hou J, Wang L et al (2021) Regulatory roles of osteopontin in human lung cancer cell epithelial-to-mesenchymal transitions and responses. Clin Transl Med 11(7):e486PubMedPubMedCentralCrossRef
89.
Qi J, Sun H, Zhang Y et al (2022) Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun 13(1):1742PubMedPubMedCentralCrossRefADS
90.
91.
Nallasamy P, Nimmakayala RK, Karmakar S et al (2021) Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 Axis. Gastroenterology 161(6):1998-2013.e1997PubMedCrossRef
92.
Matsubara E, Komohara Y, Esumi S et al (2022) SPP1 derived from macrophages is associated with a worse clinical course and chemo-resistance in lung adenocarcinoma. Cancers (Basel) 14(18):4374PubMedCrossRef
93.
Matsubara E, Yano H, Pan C et al (2023) The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages. Cancers (Basel) 15(8):2250PubMedCrossRef
94.
Vincent JL, Levi M, Hunt BJ (2022) Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med 10(2):214–220PubMedCrossRef
95.
Gibellini L, De Biasi S, Paolini A et al (2020) Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol Med 12(12):e13001PubMedPubMedCentralCrossRef
96.
van der Windt GJW, Hoogerwerf JJ, de Vos AF et al (2010) Osteopontin promotes host defense during Klebsiella pneumoniae-induced pneumonia. Eur Respir J 36(6):1337–1345PubMedCrossRef
97.
van der Windt GJW, Hoogendijk AJ, Schouten M et al (2011) Osteopontin impairs host defense during pneumococcal pneumonia. J Infet Dis 203(12):1850–1858CrossRef
98.
Ueno T, Miyazaki E, Ando M (2010) Osteopontin levels are elevated in patients with eosinophilic pneumonia. Respirology 15(7):1111–1121PubMedCrossRef
99.
Chang JH, Hung WY, Bai KJ et al (2016) Utility of plasma osteopontin levels in management of community-acquired pneumonia. Int J Med Sci 13(9):673–679PubMedPubMedCentralCrossRef
100.
MacDonald L, Alivernini S, Tolusso B et al (2021) COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. JCI Insight 6(13):e147413PubMedPubMedCentralCrossRef
101.
102.
O’Regan AW, Hayden JM, Body S et al (2001) Abnormal pulmonary granuloma formation in osteopontin-deficient mice. Am J Respir Crit Care Med 164(12):2243–2247PubMedCrossRef
103.
Hernández-Bazán S, Mata-Espinosa D, Lozano-Ordaz V et al (2022) Immune regulatory effect of osteopontin gene therapy in a murine model of multidrug resistant pulmonary tuberculosis. Hum Gene Ther 33(19–20):1037–1051PubMedCrossRef
104.
Koguchi Y, Kawakami K, Uezu K et al (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 167(10):1355–1359PubMedCrossRef
105.
van der Windt GJ, Wieland CW, Wiersinga WJ et al (2009) Osteopontin is not crucial to protective immunity during murine tuberculosis. Immunology 128(1):e766-776PubMedPubMedCentral
106.
Inomata S, Shijubo N, Kon S et al (2005) Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 30(4):203–211PubMedCrossRef
107.
Hasibuan FM, Shiratori B, Senoputra MA et al (2015) Evaluation of matricellular proteins in systemic and local immune response to Mycobacterium tuberculosis infection. Microbiol Immunol 59(10):623–632PubMedCrossRef
108.
Nau GJ, Liaw L, Chupp GL et al (1999) Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun 67(8):4223–4230PubMedPubMedCentralCrossRef
109.
Christenson SA, Smith BM, Bafadhel M et al (2022) Chronic obstructive pulmonary disease. Lancet 399(10342):2227–2242PubMedCrossRef
110.
Schneider DJ, Lindsay JC, Zhou Y et al (2010) Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J 24(1):70–80PubMedPubMedCentralCrossRef
111.
Lee SJ, Kim SH, Kim W et al (2014) Increased plasma osteopontin in frequent exacerbator and acute exacerbation of COPD. Clin Respir J 8(3):305–311PubMedCrossRef
112.
Shan M, Yuan X, Song LZ et al (2012) Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med 4(117):117ra119CrossRef
113.
Gela A, Bhongir RK, Mori M et al (2016) Osteopontin that is elevated in the airways during COPD impairs the antibacterial activity of common innate antibiotics. PloS one 11(1):e0146192PubMedPubMedCentralCrossRef
114.
115.
116.
Delimpoura V, Bakakos P, Tseliou E et al (2010) Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 65(9):782–786PubMedCrossRef
117.
Samitas K, Zervas E, Vittorakis S et al (2011) Osteopontin expression and relation to disease severity in human asthma. Eur Respir J 37(2):331–341PubMedCrossRef
118.
Kohan M, Bader R, Puxeddu I et al (2007) Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling. Clin Exp Allergy 37(10):1444–1454PubMedCrossRef
119.
Trinh HKT, Nguyen TVT, Kim SH et al (2020) Osteopontin contributes to late-onset asthma phenotypes in adult asthma patients. Exp Mol Med 52(2):253–265PubMedPubMedCentralCrossRef
120.
Akelma AZ, Cizmeci MN, Kanburoglu MK et al (2014) Elevated level of serum osteopontin in school-age children with asthma. Allergol Immunopathol (Madr) 42(4):275–281PubMedCrossRef
121.
Hillas G, Loukides S, Kostikas K et al (2013) Increased levels of osteopontin in sputum supernatant of smoking asthmatics. Cytokine 61(1):251–255PubMedCrossRef
122.
Kanemitsu Y, Ito I, Niimi A et al (2014) Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. Am J Respir Crit Care Med 190(4):472–474PubMedCrossRef
123.
Kohan M, Breuer R, Berkman N (2009) Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Respir Cell Mol Biol 41(3):290–296PubMedCrossRef
124.
Simoes DC, Xanthou G, Petrochilou K (2009) Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in chronic asthma. Am J Respir Crit Care Med 179(10):894–902PubMedCrossRef
125.
Yang HW, Park JH, Jo MS et al (2022) Eosinophil-derived osteopontin induces the expression of pro-inflammatory mediators and stimulates extracellular matrix production in nasal fibroblasts: the role of osteopontin in eosinophilic chronic rhinosinusitis. Front Immunol 13:777928PubMedPubMedCentralCrossRef
126.
Puxeddu I, Berkman N, Ribatti D et al (2010) Osteopontin is expressed and functional in human eosinophils. Allergy 65(2):168–174PubMedCrossRef
127.
Xanthou G, Alissafi T, Semitekolou M et al (2007) Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 13(5):570–578PubMedPubMedCentralCrossRef
128.
Gela A, Kasetty G, Mörgelin M et al (2016) Osteopontin binds and modulates functions of eosinophil-recruiting chemokines. Allergy 71(1):58–67PubMedCrossRef
129.
Kasetty G, Bhongir RKV, Papareddy P et al (2019) Osteopontin protects against pneumococcal infection in a murine model of allergic airway inflammation. Allergy 74(4):663–674PubMedCrossRef
130.
Kurokawa M, Konno S, Matsukura S et al (2009) Effects of corticosteroids on osteopontin expression in a murine model of allergic asthma. Int Arch Allergy Immunol 149(Supp 1):7–13PubMedPubMedCentralCrossRef
131.
Uwadiae FI, Pyle CJ, Walker SA et al (2019) Targeting the ICOS/ICOS-L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease. Allergy 74(4):650–662PubMedCrossRef
132.
Bellan M, Murano F, Ceruti F et al (2022) Increased levels of ICOS and ICOSL are associated to pulmonary arterial hypertension in patients affected by connective tissue diseases. Diagnostics (Basel) 12(3):704PubMedCrossRef
133.
Tanaka C, Fujimoto M, Hamaguchi Y et al (2010) Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum 62(6):1723–1732PubMedCrossRef
134.
Fan X, He C, Jing W et al (2015) Intracellular osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res 75(1):86–97PubMedCrossRef
135.
Shinohara ML, Lu L, Bu J et al (2006) Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7(5):498–506PubMedPubMedCentralCrossRef
Metadata
Title
Osteopontin: A Novel Therapeutic Target for Respiratory Diseases
Authors
Qi Jia
Yeling Ouyang
Yiyi Yang
Shanglong Yao
Xiangdong Chen
Zhiqiang Hu
Publication date
07-12-2023

Other articles of this Issue 1/2024

Lung 1/2024 Go to the issue

INTERVENTIONAL PULMONOLOGY

Transbronchial Lung Cryobiopsy Performed with Cone Beam Computed Tomography Guidance Versus Fluoroscopy: A Retrospective Cohort Review

STATE OF THE ART REVIEW

Mucus Transpiration as the Basis for Chronic Cough and Cough Hypersensitivity

ASTHMA

Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study

INTERSTITIAL LUNG DISEASE

Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)

EDITORIAL

LUNG Year in Review: 2023

BRONCHIECTASIS

Elevated Eosinophil Counts in Acute Exacerbations of Bronchiectasis: Unveiling a Distinct Clinical Phenotype
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits